{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-094382","form_type":"8-K","ticker":null,"cik":"0001008848","company_name":"Acorda Therapeutics, Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.862633+00:00","generated_at":"2026-05-31T10:18:05.919395+00:00","sec_items":["1.03","3.03","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Acorda Therapeutics liquidation plan confirmed; equity cancelled, management replaced","bullets":["Asset sale to Merz Pharmaceuticals closed July 10, 2024 for $185M.","Bankruptcy court confirmed Modified First Amended Joint Chapter 11 Plan of Liquidation on August 7, 2024.","All equity securities cancelled; shareholders receive no distributions under the plan.","CEO Ron Cohen, CFO Michael Gesser, and other directors/officers deemed resigned on effective date; liquidating trustee appointed.","Company to dissolve after filing final tax returns and certificate of dissolution."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-094382","json":"https://secwatch.observer/filing/0000950170-24-094382.json","markdown":"https://secwatch.observer/filing/0000950170-24-094382.md","text":"https://secwatch.observer/filing/0000950170-24-094382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/acor-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:18:05.919395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"737413fc4aada5fb96fd10649690de2135d9c171","claim":"Acorda Therapeutics, Inc. entered chapter 11 in United States Bankruptcy Court for the Southern District of New York (petition 2024-04-01).","evidence_excerpt":"On April 1, 2024, the Company, together with certain of its subsidiaries (together with the Company, the “Debtors”), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the “Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Court”) under the caption In re Acorda Therapeutics, Inc., et al. (the “Chapter 11 Proceedings”).","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the Southern District of New York"},{"label":"Petition","value":"2024-04-01"}],"fact_type":"distress_event"},{"claim_id":"09b0270ebc","claim":"Peder K. Jensen resigned as Director at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1a78c91231","claim":"Kerry Clem resigned as Chief Commercial Officer at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"312bc43c55","claim":"Thomas Burns resigned as Director at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"34555b720a","claim":"Sandra Panem resigned as Director at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"589129600f","claim":"John P. Kelley resigned as Director at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"59a4dffaf2","claim":"Neil S. Belloff resigned as General Counsel and Corporate Secretary at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"General Counsel and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"c2324d9f5a","claim":"Ron Cohen resigned as Chief Executive Officer at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c35be2115f","claim":"Michael A. Gesser resigned as Chief Financial Officer and Treasurer at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"dbf07ab7e2","claim":"John Varian resigned as Director at Acorda Therapeutics, Inc..","evidence_excerpt":"each of Ron Cohen, M.D., Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Thomas Burns, Peder K. Jensen, M.D., John P. Kelley, Sandra Panem, Ph.D., John Varian, members of the Board, and Michael A. Gesser, Chief Financial Officer and Treasurer, Neil S. Belloff, General Counsel and Corporate Secretary, and Kerry Clem, Chief Commercial Officer will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024094382/0000950170-24-094382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}